Medtronic plc.'s MDT Diabetes Management segment is dominating the headlines of late. Following the company’s receipt of the CE Mark approval for its advanced continuous glucose monitoring (CGM) ...
Aggregated real-world outcome data collected from thousands of Medtronic MiniMed 670G users indicate that patients on the system spend an average 71% of their time within an optimal glycemic range.
The FDA has expanded its indication for Medtronic’s Guardian Sensor 3, allowing patients to wear the sensor on their upper arm. The sensor is part of Medtronic’s MiniMed 670G system, and is currently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback